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Abstract
Introduction: Pulmonary embolism (PTE) is a common cardiovascular emergency. We aimed to predict mortality in the acute 
phase and to assess the development of pulmonary hypertension in the chronic period with the combined use of red cell distri-
bution width (RDW) and echocardiography (ECHO) for the prognosis of PTE.
Material and methods: Cases diagnosed with acute PTE were prospectively monitored in our clinic. The initial data of 56 patients 
were evaluated. The subjects were separated into two groups basing on RDW; group 1 had RDW ≥ 15.2%, while group 2 had 
RDW < 15.2%. 
Results: Ninety-eight patients were enrolled in the study. We established the sensitivity (73.3%) and the specificity (73.2%) of 
RDW to determine mortality in the cases with PTE. RDW ≥ 15.2% value was significant as an independent risk factor for predicting 
mortality (OR:7.9 95% CI, 1.5–40.9 p = 0.013) in acute PTE. The mean tricuspid annular plane systolic excursion (TAPSE) value 
was significantly different between the group-1 (RDW ≥ 15.2%, 2.20 cm [± 0.43] and group-2 (RDW < 15.2%, 1.85 cm [± 0.53] 
[p = 0.007]). The threshold value for tricuspid jet velocity was > 2.35m/s, the sensitivity and specificity were 76.9% and 61.9%, 
respectively for predicting mortality (AUC: 0.724, 95% CI: 0.591–0.858, p = 0.033).
Conclusion: Our results indicate that high RDW levels are an independent predictor of mortality in acute PTE. Lower TAPSE 
levels show right heart failure in PTE patients; this may also be indicative of right ventricular systolic function. We believe that 
developing new scoring systems, including parameters such as RDW, TAPSE, and tricuspid jet velocities, may be effective in 
determining the prognosis of pulmonary embolism.
Key words: chronic thromboembolic pulmonary hypertension, red cell distribution width, pulmonary embolism, tricuspid annular 
plane systolic excursion, tricuspid jet velocity
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Introduction
Pulmonary thromboembolism (PTE) is a com-
mon cardiovascular emergency. Pulmonary arte-
rial bed obstruction may lead to life-threatening 
acute, but often reversible, right ventricular 
failure. The first 30-day early mortality rate for 
PTE is between 7% and 11% [1].
Echocardiography (ECHO) is important in 
determining any right ventricular dysfunction or 
dilatation that may occur in massive/submassive 
PTE. ECHO is especially useful in discrimina-
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ting between massive PTE and other high-risk 
conditions, such as aortic dissection, pericardial 
tamponade, myocardial infarction, and cardioge-
nic shock [2, 3]. Tricuspid annular plane systolic 
excursion (TAPSE) is a simple echocardiographic 
measure of the right ventricular ejection fraction 
and tricuspid jet velocity. It is used to calculate 
pulmonary artery pressure (PAP), and may replace 
the usual parameters for detecting PTE severity 
[4]. This measure may also be able to help with 
the identification of PTE and any cases requiring 
a close follow-up. 
Red cell distribution width (RDW) is a marker 
indicating the heterogeneity of red blood cells; 
and may be useful in detecting and following PTE. 
Results from one study showed that an increase in 
RDW (> 14.6%) and the presence of shock in the 
acute phase were associated with early mortality 
in PTE [5]. 
The aim of the study was to predict mortality 
in the acute phase and prognosis and development 
of pulmonary hypertension (PHT) in the chronic 
phase by using RDW and ECHO, which are simple 
and inexpensive routine laboratory tests.
Material and methods
Study group
The study was carried out between June 
2012 and July 2013 at the chest diseases clinic 
of a university hospital, and was approved by the 
local ethical committee. New patients diagnosed 
with PTE were included in the study. These cases 
were followed up for 3 months according to the 
initial therapy, or for 6 months according to the 
risk factor assessment. The 90-day mortality rates 
of all patients were recorded.
Exclusion criteria of the study were as fol-
lows: patients < 18 years old, subjects with 
known hematologic malignancies, transfusion 
history within the last 2 weeks, with CKD (chro-
nic kidney disease) beginning dialysis, those 
receiving chemotherapy, patients with left heart 
failure, individuals undergoing treatment with 
anemia diagnosis and those without consent.
Study design
Patient data that were recorded and follo-
wed up in this study included demographic 
parameters, vital signs, risk factors for PTE, 
diagnostic imaging method [computerized to-
mography pulmonary angiography (CTPA), 
pulmonary perfusion scintigraphy, or lower 
extremity Doppler ultrasonography (USG)], 
findings of right heart failure in ECHO (PAP, 
right ventricular dilatation, TAPSE, tricuspid 
jet velocities, right ventricular diameter, RV/LV 
ratio), complications related to treatment, Wells 
score in the acute phase, laboratory parameters, 
and simplified pulmonary embolism severity 
index (sPESI). 
We treated non-massive cases with either 
standard heparin dose adjustments (80 U/kg 
bolus dose and 18 U/kg/hr continued infusion) 
according to active partial thromboplastin time 
level (aPTT, 1.5–2.5-fold to normal), or low mo-
lecular weight heparin (LMWH, 2 × 100 IU/kg); 
patients receiving either treatment plan under-
went follow-up. The subjects with massive PTE 
tissue plasminogen activator (TPA) were given 
(100 mg in 2h), and after that, standard heparin 
was administered. Oral anticoagulant treatment 
was given to patients with the appropriate clinical 
conditions, and these individuals also underwent 
follow-up. Vena cava filtration was performed 
in patients with a high contraindication of anti-
coagulation treatment and a high risk of recurrent 
venous thromboembolism. 
Echocardiographic parameters:
Echocardiographic examinations were car-
ried out with 2-D, conventional, and tissue Dop-
pler echocardiography using the Vivid 7 system 
(GE Vingmed Ultrens, Horten, Norway) with a 3.4 
MHz transducer probe. Systolic PAP was calcu-
lated by adding the mean right atrium pressure 
(5 mm Hg) to the tricuspid regurgitation pressure 
gradient (BG = 4v2) using the modified Bernoulli 
equation. Systolic PAP > 35 mm Hg was defined 
as pulmonary hypertension. Dilatation was con-
sidered in the patients with the right ventricular 
diameter parameters of parasternal > 30 mm Hg 
and mid-level > 35 mm Hg, while right ventri-
cular systolic failure was considered in those 
with TAPSE ≤ 1.5 cm. Ventricular dilation was 
considered in the subjects with RV/LV ≥ 0.9, while 
pulmonary artery hypertension was considered 
in those with tricuspid jet velocity < 2.8 – 2.9 
m/s and PAP ~ 36 mm Hg [4, 6]. 
Blood samples taken from the patients for 
hemogram analysis were examined with the 
Beckman Coulter LH-750 Hematology Analyzer. 
Reference (normal) values of RDW (calculated by 
the following: standard deviation of erythrocyte 
volume × 100/MCV) were accepted between 
11.6–16.5%. Blood was considered positive for 
troponin if it met the following criteria: troponin-I  
≥ 0.04, troponin T ≥ 0.014.
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Statistical analysis
Data characterized by a normal distribution 
were expressed as means and standard deviations. 
Parameters without such a normal distribution 
were conveyed as medians with minimum-ma-
ximum. Student’s t-test (normal distribution) or 
Mann-Whitney and Wilcoxon (non-normal distri-
bution) tests were used to compare data between 
the 2 groups. Discrete variables were contrasted 
using the Fisher’s exact test (chi-square test). The 
effects of the examined parameters on mortality 
were investigated with a  stepwise (backward) 
logistic regression analysis. ROC analysis was 
used to calculate the RDW cut-off score. All data 
were analyzed using IBM SPSS V15 (Chicago, 
USA). The values of p < 0.05 were considered 
statistically significant. 
Results
Clinical settings of patients
A total of 98 patients with acute PTE were 
initially evaluated. The mean age of all subjects 
was 67.57 years (± 16.7). Eighty-seven (88.8%) 
patients were diagnosed with CTPA, 6 (6.1%) 
-with scintigraphy, and the remaining patients 
were examined with additional methods, such as 
clinical and Doppler ultrasonographic analyses. 
As initial treatment, LMWH was used in 65 pa-
tients (66.3%), and standard heparin was applied 
in 33 persons (33.7%). Thrombolytic therapy 
was given in addition to standard heparin as an 
initial treatment in eight patients (8.2%) who 
were considered as having massive PTE. A vena 
cava filter was placed in one individual with 
persistent risk factors. Follow-up treatment was 
continued in the appropriate patients with oral 
anticoagulant. 
Clinical data, RDW values, and ECHO para-
meters of 56 prospectively monitored subjects 
meeting the study criteria were statistically 
evaluated. Fourteen of these patients (25%) died 
within the first 90 days after acute PTE. Twelve 
individuals did not come to the 6th month of the 
follow-up, and only data taken at the 3 month 
of the follow-up could be included. Thirty of 
the 56 patients were observed over the entire 6 
months. These 56 subjects were divided into 2 
RDW groups, as low-RDW (RDW < 15.2%: Gro-
up-1) and high-RDW (RDW ≥ 15.2%: Group-2) 
according to the value determined in the ROC 
curve analysis for predicting PTE mortality. The 
characteristics of the 56 patients in the study 
group are presented in Table 1.
Echocardiographic evaluation of patients
ECHO parameters of all patients were evalu-
ated and compared with RDW. The mean TAPSE 
value was 2.20 cm (± 0.43) in the group 1 (RDW 
< 15.2%) and 1.85 cm (± 0.53) in the group 2 
(RDW ≥ 15.2%). There was a significant difference 
between the two groups (p = 0.007) with regard 
to having right ventricular systolic failure. RDW 
levels significantly negatively correlated with 
the TAPSE level at ECHO assessment (Fig. 1, 
p = 0.008, r = –0.352). There was a significant 
increase in the risk of developing right ventri-
cular systolic dysfunction as the levels of RDW 
grew. Threshold values for tricuspid jet velocity 
were calculated via ROC analysis for survivor 
and non-survivors. When the threshold value 
for the tricuspid jet velocity was > 2.35 m/s, the 
sensitivity and specificity were 76.9% and 61.9%, 
respectively for predicting mortality (AUC: 0.724, 
95% CI: 0.591–0.858, p = 0.033). 
There was a statistically significant difference 
in TAPSE and tricuspid jet velocity (p = 0.018, 
p = 0.033, respectively) between the survivor 
and non-survivor groups; however, there was no 
significant difference in RV/LV ratio to predict 
mortality. TAPSE and tricuspid jet velocities were 
found to be more useful than RV/LV ratio in eva-
luating right heart failure in acute PTE (Table 2). 
There was a negative correlation between RV/
LV ratio and TAPSE (p = 0.001, r = –0.443), and 
a positive correlation between RV/LV ratio and 
tricuspid jet velocity (p = 0.025, r = 0.302).
Follow-up and outcome data
We compared the data at the first evaluation 
and at the six-month evaluation of 30 PTE pa-
tients who were followed up for six months. The 
mean PAP of the patients at the first evaluation 
was 31.37 mm Hg (± 14.78); by six months, this 
value had decreased to 24.24 mm Hg (± 7.24), 
as expected (p = 0.004). The mean tricuspid jet 
velocity value (as determined by ECHO) was 
2.28 m/s  (± 0.66) at the initial evaluation, and 
2.01 m/s (± 0.50) at the 6th month (p = 0.005). 
The mean TAPSE value was 2.24 cm (± 0.37) at 
the initial evaluation and 2.41 cm (± 0.36) at the 
6-month evaluation (p = 0.033) (Table 3).
ROC analysis was used to identify the opti-
mal RDW cut-off value for all deaths (Fig. 2). In 
the ROC analysis, the area under the curve (AUC) 
was 0.755 (95% CI; 0.622-0.860, p = 0.005) for 
RDW levels of all-cause mortality. Serum RDW ≥ 
15.2% showed sensitivity and specificity for all-
cause deaths as 73.3% and 73.2%, respectively. 
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Table 1. Baseline patient characteristics according to baseline RDW level
Total
n = 56
Group-1 
(RDW < 15.2%)
n = 32
Group-2
(RDW ≥ 15.2%)
n = 24
*p
Characteristics
Mean Age (± SD, years) 65.68 ± 16.87 60.28 ± 17.31 72.88 ± 13.48 0.005
Sex, Female (%) 34 (60.7) 19 (59.4) 15 (62.5) 1.000
Smoker (%) 12 (21.4) 9 (28.1) 3 (12.5) 0.280
Risk factors
Surgery 12 (21.4) 8 (25.0) 4 (16.7) 0.072
Immobility 27 (48.2) 11 (34.4) 16 (66.7) 0.034
Malignancy 17 (30.4) 5 (15.6) 12 (50.0) 0.013
Obesity 1 (1.8) 1 (3.1) 0 1.000
Previous embolism 6 (10.7) 2 (6.3) 4 (16.7) 0.385
FV Leiden mutation 4 (7.1) 4 (12.5) 0 0.127
Laboratory parameters
RDW (%) 15.29 ± 2.21 13.95 ± 0.65 17.09 ± 2.30 < 0.001
CRP (mg/dl) 6.59 ± 6.73 6.43 ± 7.28 6.80 ± 6.05 0.842
Hemoglobin (g/dl) 12.54 ± 1.79 12.87± 1.79 12.10 ± 1.72 0.111
BUN (mg/dl) 20.39 ± 13.95 18.05 ± 8.33 23.51 ± 18.82 0.195
O2 saturation (%) 91.83 ± 6.0 92.17± 4.93 91.37 ± 7.27 0.627
D-Dimer µg/ml (min-max) 9.19 (0.74–45) 10.88 (0.74–43.40) 6.94 (1.41–45) 0.987
**Troponin elevated (ng/ml%) 27 (48.2) 14 (43.8) 13 (54.2) 0.616
ECHO parameters
PAP (mm Hg) 35.18 ± 15.60 34.25 ± 15.53 36.47 ± 15.97 0.606
RV (cm) 32.28 ± 6.23 31.40 ± 4.44 33.45± 7.98 0.226
EF (min-max) 63.21 (45–65) 64.06 (55–65) 62.08 (45–65) 0.169
RV/LV 0.76 ± 0.23 0.73 ± 0.13 0.81 ± 0.31 0.243
TAPSE (cm) 2.05 ± 0.50 2.20 ± 0.43 1.85 ± 0.53 0.007
T. jet.vel. (m/s) 2.41 ± 0.70 2.37 ± 0.73 2.46 ± 0.67 0.649
CRP: C-reactive protein; PAP: pulmonary artery pressure; RV: right ventricular; RV/LV: right ventricle/left ventricle diameter ratio; RDW: red cell distribution width; TAPSE: 
tricuspid annular plane excursion; T. jet. vel: Tricuspid jet velocity; ± SD: standard deviation; Values are presented as means ± standard deviation
*group 1 (RDW < 15.2%) and group 2 (RDW ≥ 15.2%) are compared
**Troponin-I ≥ 0.04, Troponin-T ≥ 0.014
Statistically significant differences between survival and non-survival groups are shown in bold
Eleven (45.8%) of the 24 patients in the group 1 
(RDW < 15.2%) died and 3 (9.4%) of the 32 pa-
tients in the group 2 (RDW≥ 15.2%) died within 
ninety days (p = 0.005) (Fig. 3).
Mortality predictors of univariate analysis 
included demographics (age), laboratory para-
meters (RDW ≥ 15.2%, BUN (md/dl)), ECHO pa-
rameters (TAPSE ≤ 1.5 cm, tricuspid jet velocity 
≥ 2.35 m/s), clinical findings (respiratory rate > 
30/min), and comorbidity (chronic obstructive 
pulmonary disease, COPD), BUN, tricuspid jet 
velocity (≥ 2.35 m/s), and RDW were significant 
independent predictors of mortality in patients 
with PTE by multivariate regression analysis. 
RDW was associated with a 7.9-fold (95% CI: 
1.5–40.9, p = 0.013) increase in predicting PTE 
mortality (Table 4).
Discussion
In the present study, we aimed to determine 
the prognostic value of RDW and ECHO parame-
ters in cases with acute PTE. We found that an 
RDW cut-off value ≥ 15.2% showed a sensitivity 
of 73.3% and a specificity of 73.2% for predicting 
mortality in patients with PTE. Similarly to us, 
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Table 2. ECHO parameters of survivor or non-survivor patients with PTE
ECHO parameters Total
n = 56 (%)
Survivor
n = 42 (%)
Non-Survivor
n = 14 (%)
p
TAPSE (≤ 1.5 cm) 8 (14.3) 3 (7.1) 5 (35.7) 0.018
T. jet.vel. (≥ 2.35 m/sn) 26 (47.3) 16 (38.1) 10 (76.9) 0.033
PAP ( > 35 mm Hg) 21 (38.2) 13 (31.7) 8 (57.1) 0.170
RV/LV (≥ 0.73) 30 (53.6) 21 (50.0) 9 (64.3) 0.536
TAPSE: tricuspid anuular plane systolic excursion; T. jet vel.: tricuspid jet velocity; PAP: pulmonary artery pressure; RV/LV: right ventricle/left ventricle ratio, threshold 
values are shown in parenthesis 
Statistically significant differences between survival and non-survival groups are shown in bold
Table 3. Parameters of patients at inital and 6 month follow-up
Parameters Inıtial
(SD)
6 Moths Follow-uo
(SD)
*p
PAP (mm Hg) 31.37 ± 14.78 24.24 ± 7.24 0.004
RV (cm) 30.90 ± 4.83 29.63 ± 4.31 0.132
RV/LV 0.72 ± 0.15 0.73 ± 0.21 0.770
EF (%-min-max) 64.00 (55–65) 64.16 (50–65) 0.666
TAPSE (cm) 2.24 ± 0.37 2.41 ± 0.36 0.033
T. jet vel. (m/s) 2.28 ± 0.66 2.01 ± 0.50 0.005
RDW (%) 14.33 ± 1.0 14.7 ± 1.1 0.078
HGB (g/dl) 12.50 ± 1.77 13.02 ± 1.74 0.095
Creatinin (mg/dl) 0.85 ± 0.40 0.84 ± 0.38 0.778
BUN (mg/dl) 16.83 ± 8.10 17.3 ± 9.90 0.578
CRP (min-max) 6.69 (0.11–26.0) 1.68 (0.12–17.10) < 0.001
D-Dimer (min-max) 8.38 (1.21–40.0) 0.85 (0.17–2.20) < 0.001
SD: standart deviation; PAP: pulmonary artery pressure; RV: right ventricle; RV/LV: right ventricle/left ventricle ratio; EF: ejection fraction; TAPSE: tricuspid anuular 
plane systolic excursion; T. tet vel: tricuspid jet velocity; RDW: red blood cell distribution width; HGB: haemoglobin; BUN: blood urea nitrogen; CRP: c-reacitve protein
EF, CRP and d-dimer (non-normal distribution) were assessed by Wilcoxon test
Statistically significant differences between survival and non-survival groups are shown in bold
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Figure 1. Correlation curve between RDW and TAPSE
Ozsu et al. [7] found that RDW is a predictor of 
all causes of death with an optimal RDW value ≥ 
15%. In that study, an RDW ≥ 15% was associated 
with a 1.2-fold increase in predicting mortality 
in multivariate analysis. In a  retrospective stu-
dy with 208 PTE patients, it was found that an 
RDW value ≥ 16.25% was associated with a 4.04-
fold growth in forecasting mortality (95 % CI: 
1.229–13.335, p = 0.021) [8]. Similarly, in the pre-
sent study, we found that high RDW levels were 
associated with a 7.9-fold increase in predicting 
PTE mortality.
In a retrospective study with a primary end 
point of hospital mortality, 455 of 1539 patients 
with PTE died. In the same paper, the subjects 
were grouped as RDW > 14.8% and ≤ 14.8% by 
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Table 4. Independent predictors of PE mortality by multivarite logistic regression analysis
OR 95% CI p-value
Age, years 1.0 0.9–1 0.907
BUN > 20 mg/dl 5.2 1–25.1 0.038
RDW ≥ 15.2% 7.9 1.5–40.9 0.013
T. jet.vel. ≥ 2.35 m/s 5.5 1–28.8 0.042
CI: confidence interval; OR: odds ratio; BUN: blood urea nitrogen; RDW: red blood cell distribution width; T. tet vel: tricuspid jet velocity
Statistically significant differences between survival and non-survival groups are shown in bold
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Figure 2. Receiver-operating characteristic curve of red blood cell 
distribution width (RDW)
Figure 3. 90-day mortality assessment, survivors vs non-survivors
ROC analysis, and RDW was found to be a si-
gnificantly independent predictor of mortality 
by multivariate analysis (OR: 1.1, p = 0.002). 
The authors surmised that the increase in RDW 
was mostly due to the inflammatory response to 
oxidative stress. Furthermore, they found that 
RDW was significantly elevated in patients with 
cardiopulmonary disease, those who had under-
gone abdominal surgery or neurosurgery, and 
non-survivors [9]. In the current study, RDW was 
significantly raised in all causes of death within 
90 days after PTE. 
The mechanism as to why increased levels 
of RDW are linked to mortality is not yet clear. 
However, many studies suggest that growths 
in RDW levels in the acute phase of PTE are 
caused by increases in inflammatory cytokines, 
suppression of bone marrow function, decreases 
in erythrocyte maturation, and rises in oxidative 
stress. RDW levels tend to be higher particularly 
in patients with mortal diseases [10, 11].
Another important assessment of PTE pro-
gnosis is the development of right heart failure. 
In the current study, in addition to the relation-
ship between RDW level and mortality, we also 
assessed the connection between RDW level and 
right ventricular function. Furthermore, right 
ventricular function plays a substantial role in 
the development of massive/submassive PTE. 
The assessment of right ventricular func-
tion is difficult when it is asymptomatic and the 
dimensions are normal. In recent years, studies 
have shown that right ventricular function can be 
reliably assessed via cardiac catheterization, MR 
(magnetic resonance), radionuclide ventriculo-
graphy, and 3D echocardiography [12]. However, 
these methods are not readily available and are 
not able to be performed in the short term. Among 
the new methods, TAPSE (as measured by ECHO) 
is a readily available method. It is a simple echo-
cardiographic measure of the right ventricular 
ejection fraction. Longitudinal RV measurements 
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< 16 mm indicate right ventricular dysfunc-
tion. Most of the right ventricular motion can 
be explained by the subendocardial-myocardial 
fibers that are longitudinally located in the thin 
right ventricular wall. Therefore, it is thought 
that the tricuspid annular excursion that occurs 
between the long axis annular plane and apex can 
provide important information about global right 
ventricular functions. TAPSE is recommended 
for routine use, it provides direct information 
about right ventricular systolic functions, and 
has a good correlation with the RV ejection frac-
tion [6, 13]. 
Tricuspid jet velocity is a parameter that is 
used to measure right ventricular systolic pressu-
re by adding right atrium pressure. Generally, 
tricuspid jet velocity is 2.8–2.9 m/s, suggesting 
that the sPAP is about 36 mm Hg, assuming that 
the right atrium pressure is 3-5 mm Hg [6].
In their study, Park et al. [13] established 
that both TAPSE and tricuspid annular systolic 
velocity (TASV) were significantly correlated with 
echocardiographic parameters in terms of right 
heart failure. In Park’s study, the mean TAPSE of 
44 PTE patients was 1.5 (± 4 cm) at the time of 
admission. This value increased to 2.2 (± 3 cm) 
at follow-up, which was significant. In the pre-
sent study, we observed a significant difference 
between admission and 6-month follow-up values 
of TAPSE and tricuspid jet velocity used in the 
measurement of PAP.
Pruszczyk et al. [14] found that TAPSE was 
preferred to the RV/LV (> 0.9) ratio for predicting 
30-day mortality in studies investigating the 
prognostic value of ECHO in normotensive PTE 
patients. In the current study, there was a signifi-
cant difference in TAPSE and tricuspid jet velocity 
between the survivors and non-survivors (p = 
0.018, p = 0.033, respectively). However, there 
was no significant difference between survivors 
and non-survivors with regard to the RV/LV ratio. 
Only tricuspid jet velocity ≥ 2.35 (m/sec) was 
found to be an independent risk factor for mor-
tality in multivariate logistic regression analysis. 
TAPSE and tricuspid jet velocities were found to 
be more valuable than RV/LV ratio in predicting 
mortality in acute PTE. 
In the present study, the TAPSE values of the 
group 1 were significantly higher than TAPSE va-
lues of the group 2 (p = 0.007). Furthermore, the 
TAPSE values of the group 2 revealed a decrease 
in right ventricular systolic function. Although 
the TAPSE values measured in our study are not 
as low as recommended in the guidelines, there 
was a significant negative correlation between 
RDW and TAPSE (p = 0.008, r = –0.352). Our 
current results revealed that there is a significant 
increase in the risk of developing right ventri-
cular systolic dysfunction with increasing RDW 
levels. Tricuspid jet velocities and RV/LV values 
were not significantly different between the two 
groups. However, there was a negative correlation 
between RV/LV ratio and TAPSE and a positive 
correlation between RV/LV ratio and tricuspid 
jet velocity. On the whole, these data reveal that 
many parameters can provide valuable informa-
tion about right heart failure, but only RDW level 
and TAPSE level are correlated. 
In the current study, we excluded hematolo-
gic malignancy patients, subjects with malignant 
growth who had received active chemotherapy, 
pregnant women, patients with chronic renal 
failure undergoing dialysis, and those who had 
received erythrocyte transfusion within the past 
2 weeks; these subjects were excluded because 
these conditions may increase RDW levels. Howe-
ver, these stringent exclusion criteria and patient 
inconsistency in follow-ups resulted in a small 
number of subjects in the current study. This can 
be considered a limitation of our study. Another 
weak point is that the relationship between in-
crease of RDW level and chronic thromboembolic 
pulmonary hypertension (CTEPH) could not be 
determined due to the absence of pulmonary 
hypertension in 30 patients during the 6-month 
follow-up. In their study, Vittorio Peng et al. [15] 
found that the incidence of CTEPH was 1% at 
the 6-month follow-up, 3.1% at 1-year follow-up, 
and 3.8% at 2-year follow-up. Other studies have 
reported the incidence of CTEPH as 1.3% [16] and 
5.1% [17] at 1-year follow-up. It is not surprising 
that we have not seen any pulmonary hyperten-
sion development in the current study due to the 
short observation period and limited number of 
patients followed up for the full 6 months.
Conclusions
In conclusion, the results of the current study 
indicate that a high RDW level can be helpful as 
an independent predictor of mortality in acute 
PTE. Therefore, close monitoring of these patients 
can be useful in the clinic. Furthermore, in our 
study the increase in RDW levels have correlated 
with the TAPSE level, which indicates the pre-
sence of right heart failure in PTE patients and 
may predict right ventricular systolic function.
Basing on the results of the study, we believe 
that after randomized clinical trials with more pa-
tients, new scoring systems should be developed 
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that include parameters such as RDW, TAPSE, 
and tricuspid jet velocities, which may be useful 
in predicting the prognosis of patients with PTE.
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